Platelet ActivationBlood PlateletsPlatelet AggregationThrombosisPlatelet AdhesivenessAtherosclerosisEmbolism, CholesterolPlatelet CountPlatelet Membrane GlycoproteinsPlatelet Aggregation InhibitorsPlatelet Factor 4P-SelectinCarotid Artery ThrombosisThrombinPlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet Glycoprotein GPIb-IX Complexbeta-ThromboglobulinAspirinAdenosine DiphosphateBlood CoagulationPlatelet Function TestsArteriosclerosisThromboxane A2Platelet TransfusionPlatelet Activating FactorFibrinogenThromboxane B2ThromboplastinBleeding TimeReceptors, Purinergic P2Y12TiclopidineRisk Factorsvon Willebrand FactorPlatelet Membrane Glycoprotein IIbPlaque, AtheroscleroticNiacinEndothelium, VascularStrokeFibrinolysisCardiovascular DiseasesThrombocytopeniaC-Reactive ProteinCollagenBiological MarkersReceptors, ThrombinCoronary ThrombosisHemorrhageMegakaryocytesCoronary Artery DiseaseHemostasisAntigens, CD63InflammationSerotoninDual Specificity Phosphatase 2RegistriesThromboxanesMyocardial InfarctionEndothelial CellsAntigens, Human PlateletApyraseFlow CytometryReceptor, PAR-1Prospective Studies15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidReceptors, CollagenPurinergic P2Y Receptor AntagonistsPlasminogen Activator Inhibitor 1Prostaglandin Endoperoxides, SyntheticDrug Therapy, CombinationCrotalid VenomsCytoplasmic GranulesApolipoproteins ECalciumReceptors, ThromboxaneCells, CulturedHypolipidemic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsRisk AssessmentImmunoglobulin Fab FragmentsCase-Control StudiesFollow-Up StudiesEpoprostenolThrombastheniaRistocetinReceptors, Purinergic P2Y1CD40 LigandAntibodies, MonoclonalHeparinHemorheologyPhosphorylationPlatelet-Rich PlasmaBlood ProteinsHirudinsEpinephrinePlatelet Factor 3Treatment OutcomeArachidonic AcidBernard-Soulier SyndromeKineticsSignal Transduction